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Glycolytic and lipogenic inhibitors have proven unsuccessful in cancer treatment strategies. In this issue of
Cancer Cell, Flaveny and colleagues target the liver-X-receptor with an inverse agonist and show that key
glycolytic and lipogenic genes are suppressed, leading to apoptosis of tumor cells without an effect on
non-malignant cells.The identification of novel target mecha-
nisms that can successfully reduce tumor
development or tumor metastasis is
a major challenge to advance current
cancer therapeutics. This is particularly
crucial for tumors where efficient thera-
pies or chemotherapies are poor. The
molecular features of the nuclear receptor
(NR) family members make them highly
favorable druggable targets of both
synthetic and natural ligands. NRs are
typically activated/deactivated by binding
of NR-specific agonist or antagonist to
their ligand-binding pocket located in the
ligand-binding domain of the NRs. NRs
are ligand-activated transcription factors;
thus, the recruitment of agonist/antago-
nist leads to altered transcription rates,
and subsequent expression levels, of
their target genes. For instance, therapies
designed to target specific members of
the NR family have been successful in
the quest to defeat breast and prostate
cancers. Estrogen receptors (ERs) can
be targeted directly by anti-estrogens
and selective ER modulators (SERMs;
tamoxifen and raloxifene) while androgen
receptors (ARs) are similarly targeted in
prostate cancer treatment.
The two ‘‘liver-X-receptors’’ LXRa and
LXRb are among the emerging newer
drug targets within the NR family with
well-known functions in cholesterol, fatty
acid, and glucose metabolism and as
modulators of immune responses (Ja-
kobsson et al., 2012). Accumulating
evidence points to important roles of
LXRs in a variety of malignancies
and the potential therapeutic capability
of their ligands. Several oxysterols areendogenous LXR agonists that induce
the transcriptional activity of LXRs; how-
ever, many natural LXR modulators have
been discovered and synthetic LXR mod-
ulators developed (Viennois et al., 2012).
LXRs have multiple roles in cancer
biology. They suppress the proliferation
of a variety of human cancer cells, target-
ing the cell cycle at several points
(Jakobsson et al., 2012). It was also
observed that tumors produce LXR ago-
nists (oxysterols) that inhibit a robust
immune response (Villablanca et al.,
2010). Therefore, tumors did not escape
immune surveillance in mice lacing
LXRa; hence, tumor growth was inhibited
in the LXRa null mice.
LXRs are established cholesterol sen-
sors where their transcriptional activation
regulates several pathways in lipid and
cholesterol metabolism, and mounting
evidence suggests that deregulated
cholesterol metabolism is a feature of
many malignancies where LXRs appear
to play a pivotal role (nicely reviewed in
Bovenga et al., 2015). The link between
LXR and cholesterol metabolism in
cancers was recently strengthened in a
robust study reporting on the potential of
LXR (here specifically LXRb) to reduce
tumor invasion in melanoma (Pencheva
et al., 2014). Activation of LXRb induced
expression and secretion of apolipopro-
tein E (ApoE), which is a potent suppres-
sor of tumor metastasis. ApoE released
in the tumor microenvironment inhibits
invasiveness of melanomas by targeting
LDLR-related protein 1 (LRP-1 receptor)
on melanoma cells and endothelial
recruitment and migration via LDLR-Cancer Crelated protein 8 (LRP8) receptors. More-
over, LXR agonists suppressed growth of
tumors resistant to the chemotherapeutic
agent dacarbazine and BRAF inhibitor ve-
murafenib and showed strong anti-tumor
effects when combined with either of
these two agents.
Altered metabolism in cancer cells is a
well know phenomenon. Aerobic glycol-
ysis, known as the Warbug effect, is the
preferred way to produce energy and sus-
tain substrates for fast-growing cancer
cells, even when other metabolites are
available (Warburg et al., 1927). The War-
bug effect is a key component of meta-
bolic reprogramming underlying tumor
growth and invasiveness. Cancer cells
also show an increased lipogenic activity;
thus, glycolytic and lipogenic inhibitors
have been extensively studied in anti-tu-
mor treatment strategies. Unfortunately,
none of the approaches made it to the
clinic because of severe off-target effects,
including excessive weight loss and cell
toxicity (Pelicano et al., 2006; Tu et al.,
2005).
In this issue of Cancer Cell, Flaveny
et al. (2015) target LXR by designing
and synthesizing an inverse agonist
(SR9243). They show that both the
Warbug effect and lipogenesis are in-
hibited in cancer cells upon treatment
with SR9243, and this consequently
leads to apoptosis of cancer cells. Intrigu-
ingly, they report a significant anti-tumor
activity of SR9243, but the treatment
spares non-malignant cells, thereby
avoiding the detrimental weight loss
and toxicity off-target effects reported in
previous studies. The authors proposeell 28, July 13, 2015 ª2015 Elsevier Inc. 3
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the rapidly growing cancer cells to
‘‘normal’’ metabolic cells that cannot
sustain cancer cell growth, and this trig-
gers apoptosis of the cancer cells. The
authors extend our molecular under-
standing of the transcriptional network of
LXRs by introducing an inverse agonist.
In the unliganded form, LXRs are associ-
ated with transcriptional corepressors.
Upon agonist activation, LXRs undergo
a conformational change where the
corepressors dissociate and transcrip-
tional coactivators are recruited. SR9243
interacts with LXRs and strengthens
the binding of LXRs to corepressors,
and thereby this inverse agonist sup-
presses LXR-mediated transcription of
target genes to below basal levels.
Furthermore, SR9243 sensitizes chemo-
therapy treatment using cytotoxic drugs
(50-fluorouracil and cisplatin) in a combi-
nation treatment strategy. Convincingly,
in vivo experiments using xenograft
models confirmed the anti-tumor effect
of SR9243 and reduced expression of
glycolytic lipogenic enzymes without
inducing weight loss.
Multiple studies report on the anti-in-
flammatory feature of LXRs (Jakobsson
et al., 2012), and studies have reported
that tumors produce LXR agonists to4 Cancer Cell 28, July 13, 2015 ª2015 Elseviavoid the body’s tumor immune surveil-
lance (Villablanca et al., 2010). Flaveny
et al. (2015) show that SR9243 specifically
induces expression of TNF-a in tumor
cells and suggest that SR9243 could
‘‘unmask’’ tumors to be recognized by
the immune system. Cytokines in the
tumor microenvironment are acknowl-
edged as important factors involved in
the control of tumor growth. Interestingly,
a recent study linked LXR-mediated
survival rates and tumor free animals
in lung cancer xenograft models to
increased interferon-g production (Wang
et al., 2014). While the anti-inflammatory
role of LXR is well documented, the cross
talk between the effect of LXR signaling
in metabolism and the LXR-mediated
modulation of the immune response
dealing with tumors has only recently
been investigated. While Flaveny et al.
(2015) provide interesting evidence that
targeting LXRs to suppress glycolysis
and lipogenesis is a promising new
strategy for cancer treatment, further
studies investigating the impact and
association of LXR signaling in meta-
bolism, immunity/inflammation, and pro-
liferationmight unravel novel mechanisms
to advance the battle against cancer.
And the inverse agonist SR9243 could
prove a valuable tool in this quest.er Inc.REFERENCES
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In this issue of Cancer Cell, Mohammad et al. describe LSD1, a histone demethylase, as a therapeutic target
in SCLC with a unique epigenetic signature to predict drug sensitivity. Inhibition of LSD1 reduces cell prolif-
eration and stem cell maintenance while promoting cell differentiation and reducing tumor growth in preclin-
ical models.Small cell lung carcinoma (SCLC) is one of
the most genetically complex cancers
(Peifer et al., 2012). Beyond mutations,
epigenetic changes also play a key role
in promoting aggressive behavior ofSCLC. 31,000 patients are diagnosed
with SCLC annually in the United States,
a majority of whom have widely dissemi-
nated disease at presentation and will
succumb to their cancer within a yeardespite current treatments. Unlike non-
small cell lung carcinoma (NSCLC), where
a growing number of druggable genetic
alterations have transformed treatment
(e.g., EGFR mutations and ALK, RET,
